The past few years have witnessed enormous progresses in the development of antibody-
drug conjugates (ADCs). Consequently, comprehensive analysis of ADCs in biological …

Targeted therapy has been recently highlighted due to the reduction of side effects and
improvement in overall efficacy and survival from different types of cancers. Considering the …

Key defining attributes of an antibody–drug conjugate (ADC) include the choice of the
targeting antibody, linker, payload, and the drug‐to‐antibody ratio (DAR). Historically, most …

Approximately 25% of breast cancer patients with HER2 overexpression tend to have a high
risk of disease progression and death. Various HER2-targeting therapies have been …

Daratumumab, a humanized monoclonal antibody utilized in treating immunoglobulin light-
chain amyloidosis and relapsed/refractory multiple myeloma, was quantified in rat serum …

The therapeutic concept of antibody drug conjugates (ADCs) is to selectively target tumour
cells with small molecule cytotoxic drugs to maximise cell kill benefit and minimise healthy …

Implementation of immunocapture LC–MS methods to characterize the pharmacokinetic
profile of large molecule drugs has become a widely used technique over the past decade …

An efficient, large-scale manufacturing process is described for XMT-1864/TFA (1-TFA), an
auristatin F derivative, used as a novel, highly potent, cytotoxic warhead in Mersana's …

Antibody-drug conjugate (ADC) plays a vital role in oncology indications. The efficacy and
toxicity of ADC generally depend on the concentration of the drugs in the body system, and …

胃癌发生隐匿, 恶性程度较高, 对传统放化疗不敏感, 预后差, 因此, 研发新型抗胃癌药物迫在眉睫
. 抗体偶联药物(Antibody-drug conjugate, ADC) 是由单克隆抗体经特定的连接子与细胞毒药物 …